In summary, pterostilbene in combination with mitochondrial cofactors treatment activates SIRT3 and UPRmt as compensatory mechanisms as well as enhance sirtuins’ levels and mitochondrial activity in several cell models of mitochondrial diseases. The gene discussed is SIRT3; the disease is inborn mitochondrial metabolism disorder.